Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 48 studies | 51% ± 20% | |
fibroblast | 22 studies | 28% ± 11% | |
smooth muscle cell | 18 studies | 24% ± 7% | |
endothelial cell of artery | 15 studies | 52% ± 23% | |
vein endothelial cell | 15 studies | 59% ± 20% | |
endothelial cell of vascular tree | 14 studies | 37% ± 16% | |
endothelial cell of lymphatic vessel | 13 studies | 32% ± 10% | |
type I pneumocyte | 12 studies | 37% ± 13% | |
pericyte | 11 studies | 35% ± 28% | |
capillary endothelial cell | 10 studies | 57% ± 20% | |
adipocyte | 10 studies | 47% ± 15% | |
basal cell | 9 studies | 25% ± 10% | |
epithelial cell | 6 studies | 29% ± 9% | |
type II pneumocyte | 5 studies | 23% ± 9% | |
cardiac muscle cell | 5 studies | 27% ± 6% | |
endothelial cell of sinusoid | 4 studies | 57% ± 24% | |
glomerular endothelial cell | 3 studies | 34% ± 0% | |
abnormal cell | 3 studies | 22% ± 5% | |
extravillous trophoblast | 3 studies | 24% ± 5% | |
endocardial cell | 3 studies | 72% ± 5% | |
glial cell | 3 studies | 28% ± 8% | |
adventitial cell | 3 studies | 23% ± 3% | |
chondrocyte | 3 studies | 25% ± 4% | |
myofibroblast cell | 3 studies | 32% ± 17% | |
Schwann cell | 3 studies | 35% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 94% | 34375.48 | 1359 / 1445 | 98% | 127.51 | 180 / 183 |
stomach | 97% | 22302.51 | 349 / 359 | 93% | 102.06 | 266 / 286 |
breast | 100% | 33196.23 | 457 / 459 | 90% | 59.74 | 1004 / 1118 |
intestine | 98% | 36426.18 | 948 / 966 | 91% | 59.94 | 477 / 527 |
lung | 96% | 17429.97 | 557 / 578 | 91% | 68.30 | 1053 / 1155 |
skin | 91% | 21045.72 | 1652 / 1809 | 93% | 64.56 | 438 / 472 |
thymus | 99% | 26977.05 | 649 / 653 | 83% | 48.67 | 502 / 605 |
prostate | 97% | 22631.24 | 237 / 245 | 83% | 40.90 | 415 / 502 |
bladder | 100% | 37672.24 | 21 / 21 | 75% | 33.50 | 380 / 504 |
uterus | 100% | 44280.84 | 170 / 170 | 73% | 33.20 | 335 / 459 |
adrenal gland | 97% | 17898.29 | 250 / 258 | 69% | 35.36 | 159 / 230 |
ovary | 70% | 9711.23 | 126 / 180 | 84% | 54.36 | 360 / 430 |
kidney | 72% | 9627.65 | 64 / 89 | 77% | 79.64 | 692 / 901 |
pancreas | 43% | 4006.33 | 140 / 328 | 95% | 84.72 | 169 / 178 |
adipose | 100% | 44668.22 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 68608.24 | 1335 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 28810.62 | 841 / 861 | 0% | 0 | 0 / 0 |
spleen | 85% | 10514.03 | 205 / 241 | 0% | 0 | 0 / 0 |
muscle | 81% | 10128.90 | 649 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 69.21 | 36 / 45 |
eye | 0% | 0 | 0 / 0 | 73% | 22.43 | 58 / 80 |
liver | 2% | 264.13 | 5 / 226 | 39% | 13.61 | 159 / 406 |
lymph node | 0% | 0 | 0 / 0 | 38% | 9.36 | 11 / 29 |
brain | 0% | 41.27 | 10 / 2642 | 23% | 7.02 | 164 / 705 |
peripheral blood | 0% | 6.95 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001525 | Biological process | angiogenesis |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0007224 | Biological process | smoothened signaling pathway |
GO_0006954 | Biological process | inflammatory response |
GO_0006898 | Biological process | receptor-mediated endocytosis |
GO_0007162 | Biological process | negative regulation of cell adhesion |
GO_0031100 | Biological process | animal organ regeneration |
GO_0072359 | Biological process | circulatory system development |
GO_0016525 | Biological process | negative regulation of angiogenesis |
GO_0001938 | Biological process | positive regulation of endothelial cell proliferation |
GO_0030154 | Biological process | cell differentiation |
GO_0001666 | Biological process | response to hypoxia |
GO_0007420 | Biological process | brain development |
GO_0009410 | Biological process | response to xenobiotic stimulus |
GO_0006629 | Biological process | lipid metabolic process |
GO_0007566 | Biological process | embryo implantation |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0005796 | Cellular component | Golgi lumen |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005925 | Cellular component | focal adhesion |
GO_0098797 | Cellular component | plasma membrane protein complex |
GO_0005604 | Cellular component | basement membrane |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0001540 | Molecular function | amyloid-beta binding |
GO_0070052 | Molecular function | collagen V binding |
GO_0050750 | Molecular function | low-density lipoprotein particle receptor binding |
GO_0030021 | Molecular function | extracellular matrix structural constituent conferring compression resistance |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | HSPG2 |
Protein name | Basement membrane-specific heparan sulfate proteoglycan core protein (HSPG) (Perlecan) (PLC) [Cleaved into: Endorepellin; LG3 peptide] Heparan sulfate proteoglycan 2 Perlecan proteoglycan 2 HSPG2 protein Heparan sulfate proteoglycan |
Synonyms | |
Description | FUNCTION: Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development.; FUNCTION: [Endorepellin]: Anti-angiogenic and anti-tumor peptide that inhibits endothelial cell migration, collagen-induced endothelial tube morphogenesis and blood vessel growth in the chorioallantoic membrane. Blocks endothelial cell adhesion to fibronectin and type I collagen. Anti-tumor agent in neovascularization. Interaction with its ligand, integrin alpha2/beta1, is required for the anti-angiogenic properties. Evokes a reduction in phosphorylation of receptor tyrosine kinases via alpha2/beta1 integrin-mediated activation of the tyrosine phosphatase, PTPN6.; FUNCTION: [LG3 peptide]: Has anti-angiogenic properties that require binding of calcium ions for full activity. |
Accessions | A0A0U1RQT3 ENST00000427897.1 H0Y5A9 ENST00000644714.1 ENST00000635682.1 B6EU51 A0A3B3IT11 H7BYA5 O43834 ENST00000374676.4 A0A2R8YH07 P98160 ENST00000374673.4 ENST00000374695.8 Q2VPA1 |